GlassScriptPhysician profile
Ashraf A Elshami
NPI 1306842968
$2,073.17
in general payments reported to CMS, 2019-2025
22 companies · $434 in 2025
The $434 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $245 · 2021: $227 · 2022: $198 · 2023: $334 · 2024: $256 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990 · Education: $34.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.82 |
| Education | $34.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $409.88 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $329.48 | 2019-2021 | |
| United Therapeutics Corporation | $145.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.72 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Amgen INC. | $130.43 | 2023-2024 | Tavneos, Tezspire |
| Actelion Pharmaceuticals US, INC. | $124.48 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $107.41 | 2021-2023 | Dupixent |
| Grifols USA, LLC | $101.26 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $91.87 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.82 | 2019-2025 | Ofev |
| Genentech USA, INC. | $73.76 | 2019 | |
| Viatris Specialty LLC | $48.50 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $45.67 | 2019-2023 | Nucala |
| Inspire Medical Systems, INC. | $44.54 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $36.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $35.68 | 2019-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $34.43 | 2022 | |
| Axsome Therapeutics, INC. | $22.36 | 2025 | Sunosi |
| Seqirus USA INC | $19.74 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.66 | 2019 | |
| Phadia US INC. | $15.11 | 2022 | |
| Harmony Biosciences LLC | $14.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Elshami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.